RAY B logo

RaySearch Laboratories AB (publ) Stock Price

OM:RAY B Community·SEK 6.2b Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 18 Fair Values set on narratives written by author

RAY B Share Price Performance

SEK 181.60
-50.90 (-21.89%)
SEK 230.60
Fair Value
SEK 181.60
-50.90 (-21.89%)
21.2% undervalued intrinsic discount
SEK 230.60
Fair Value
Price SEK 181.60
alex30free SEK 230.60
AnalystConsensusTarget SEK 330.00
AnalystHighTarget SEK 370.00

RAY B Community Narratives

alex30free·
Fair Value SEK 230.6 21.2% undervalued intrinsic discount

High-Tech Precision Play

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystConsensusTarget·
Fair Value SEK 330 45.0% undervalued intrinsic discount

Aging Population And AI Integration Will Expand Oncology Market

0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AnalystHighTarget·
Fair Value SEK 370 50.9% undervalued intrinsic discount

AI-Powered Radiotherapy Platforms Will Deepen Clinical Adoption And Strengthen Long-Term Earnings Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
RAY B logo
RaySearch Laboratories

High-Tech Precision Play

1. The Narrative: The High Tech Precision Play The narrative for RaySearch is that of a highly specialized software leader in the oncology market.Read more

View narrative
32
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
SEK 230.6
21.2% undervalued intrinsic discount
Fair Value
Revenue
10% p.a.
Profit Margin
20%
Future PE
25x
Price in 2031
SEK 315.76
SEK 330
45.0% undervalued intrinsic discount
Revenue
12.76% p.a.
Profit Margin
24.54%
Future PE
28.75x
Price in 2029
SEK 396.62
SEK 370
50.9% undervalued intrinsic discount
Revenue
15.44% p.a.
Profit Margin
23.39%
Future PE
31.67x
Price in 2029
SEK 446.8
SEK 290
37.4% undervalued intrinsic discount
Revenue
16.84% p.a.
Profit Margin
23.28%
Future PE
25.05x
Price in 2029
SEK 350.53

Trending Discussion

Updated Narratives

RAY B logo

High-Tech Precision Play

Fair Value: SEK 230.6 21.2% undervalued intrinsic discount
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RAY B logo

RAY B: Dividend Commitment And Adaptive Therapy Expansion Will Support Stronger Outlook

Fair Value: SEK 330 45.0% undervalued intrinsic discount
9 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RAY B logo

AI-Powered Radiotherapy Platforms Will Deepen Clinical Adoption And Strengthen Long-Term Earnings Potential

Fair Value: SEK 370 50.9% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet, undervalued and pays a dividend.

1 Risk
4 Rewards

RaySearch Laboratories AB (publ) Key Details

SEK 1.3b

Revenue

SEK 101.9m

Cost of Revenue

SEK 1.2b

Gross Profit

SEK 1.0b

Other Expenses

SEK 227.8m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 15, 2026
6.64
92.42%
16.95%
0%
View Full Analysis

About RAY B

Founded
2000
Employees
458
CEO
Johan Lof
WebsiteView website
www.raysearchlabs.com

RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer treatment worldwide. The company offers RayStation, a treatment planning system for cancer centers; RayCare, an oncology information system for clinics; RayIntelligence, cloud-based oncology analytics system that cancer centers can use to gather, structure and analyze data; and RayCommand, a treatment control system designed to link the treatment machine and the treatment planning and oncology information systems. It also provides µ-RayStation* (Micro-RayStation), a software platform for planning and evaluation in small animal irradiation research; RayPlan, a treatment planning system; DrugLog, which verifies the identity and concentration of compounded injectables before administered to a patient; RayMigrate, allows users to convert Pinnacle patient data to RayStation format and/or to DICOM format; and machine learning and liver ablation solutions. It has collaboration with Vision RT for integration of MapRT with RayStation treatment planning system. The company was founded in 2000 and is headquartered in Stockholm, Sweden.